Gossamer Bio Inc (NASDAQ:GOSS) major shareholder Fund V. Gp L.P. Omega sold 112,776 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $21.22, for a total transaction of $2,393,106.72. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of NASDAQ GOSS traded up $0.04 during trading hours on Tuesday, hitting $21.42. 2,796 shares of the stock were exchanged, compared to its average volume of 345,709. The company has a debt-to-equity ratio of 0.09, a quick ratio of 17.80 and a current ratio of 17.80. The company has a market cap of $1.31 billion and a PE ratio of -0.95. The company’s fifty day simple moving average is $19.60 and its two-hundred day simple moving average is $19.77. Gossamer Bio Inc has a 1-year low of $15.59 and a 1-year high of $25.06.
Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.18). As a group, sell-side analysts expect that Gossamer Bio Inc will post -2.93 EPS for the current fiscal year.
Several research firms recently issued reports on GOSS. ValuEngine upgraded shares of Gossamer Bio from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Tuesday, August 20th. Finally, Evercore ISI set a $30.00 price target on shares of Gossamer Bio and gave the stock a “buy” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $28.00.
Gossamer Bio Company Profile
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.
Recommended Story: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.